Azathioprine Tablets (Xinyi) Scope of Application

The scope of application for Azathioprine tablets includes these Oncology Diseases:

Acute and chronic leukaemia: better recent efficacy for chronic granulocytic leukaemia, fast acting, but short remission period
Acquired hemolytic anaemia: idiopathic thrombocytopenic purpura, systemic lupus erythematosus
Chronic rheumatologic arthritis
Chronic active hepatitis (hepatitis associated with autoimmunity)
Primary biliary cirrhosis
Hyperthyroidism, myasthenia gravis
Adjuvant therapy: others: chronic non-specific ulcerative colitis, segmental enteritis, polyneuritis, lupus nephritis, proliferative nephritis, Wegener’s granulomatosis, etc.

Azathioprine Tablets (Xinyi) Characteristics

Ingredients: Each tablet contains azathioprine 50mg.

Characteristics: This product is light yellow tablet.

Specification: 50mg, 60 tablets pack.

Storage: Shielded from light and kept sealed.

Effective period: 24 months, indicating the time for the drug to maintain its effectiveness and safety.

Execution standard: Chinese Pharmacopoeia, 2005 Edition, Part II.

Approval number: State Drug License H31021422

Revision Date: Approval Date: January 16, 2007

Manufacturer: Company name: Shanghai Xinyi Pharmaceutical Co.

Guidelines for the use of Azathioprine Tablets (Xinyi)

Usage and dosage: 1.Oral 1.5mg~4mg/kg per day, once a day or divided oral;
2. For allogeneic transplantation, 2mg～5mg/kg daily, once a day or divided oral intake;
3. Leukemia, 1.5mg～3mg/kg daily, once a day or divided orally.

Adverse reactions: similar to mercaptopurine but slightly less toxic; can cause bone marrow suppression, hepatic impairment, teratocarcinoma; can also occur rash; occasionally see myasthenia.

Drug Restrictions

CONTRAINDICATIONS: Contraindicated in patients known to be highly allergic to the product.

Precautions:

It causes liver function damage, so liver function poor people avoid use; it can also cause rash; and occasionally cause muscle atrophy; strictly check the blood picture during the use of drugs.

Azathioprine Tablets (Xinyi) Interactions

Allopurinol can inhibit mercaptopurine (the latter is the active metabolite of azathioprine) metabolism into inactive products. As a result of mercaptopurine toxicity increasing, when the two must be taken at the same time, the dose of azathioprine should be greatly reduced. Azathioprine can reduce the rate of inactivation of 6-mercaptopurine. 6-mercaptopurine is inactivated through the following ways: enzyme S-methylation, oxidation of the enzyme does not relate to the enzyme, or by the xanthine oxidase converted to thiolate oxidase to thiopurines, etc. Azathioprine reacts with sulfhydryl compounds such as glutathione and acts as a precursor drug by slowly releasing 6-mercaptopurine in tissues.

Note: If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYueMed. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.